Third Hospital of Shanxi Medical University
山西医科大学第三医院
Listed for 9 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Third Hospital of Shanxi Medical University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌5 papers led
- Hepatocellular carcinoma肝细胞癌23 papers led
- Osteosarcoma骨肉瘤5 papers led
- Multiple myeloma多发性骨髓瘤2 papers led
- Aplastic anaemia再生障碍性贫血2 papers led
- IgG4-related diseaseIgG4相关性疾病2 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
- Gaucher disease戈谢病0 papers led
Not listed for: Nasopharyngeal carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 5 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Taiyuan for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led5
- SECTM1 acts as an immune-related biomarker of poor prognosis and promotes cancer progression by modulating M2 macrophage polarization in esophageal squamous cell carcinoma.
- Multi-omics analysis reveals immunosuppression in oesophageal squamous cell carcinoma induced by creatine accumulation and HK3 deficiency.
- Sintilimab-induced autoimmune diabetes mellitus manifesting as diabetic ketoacidosis in a patient with advanced esophageal squamous cell carcinoma.
- miR-140-3P Induces Chemotherapy Resistance in Esophageal Carcinoma by Targeting the NFYA-MDR1 Axis.
- FBXW7 inhibits the progression of ESCC by directly inhibiting the stemness of tumor cells.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 23 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Taiyuan for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led23
- Regulatory Role and Biomarker Potential of Gut Microbiota Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease to Hepatocellular Carcinoma.
- A Macrophage-Derived 7-Gene Signature Predicts Prognosis and Therapeutic Response in Hepatocellular Carcinoma.
- Comprehensive Bibliometric Analysis of Prediction Models for HCC: Current Trends and Future Prospects.
- Exosomal CLRN1-AS1 restrains hepatocellular carcinoma cell proliferation and migration via targeting miR-320c/SRSF7 signaling by using cellular thermal and medical thermal imaging.
- VPS45 Contributes to the Progression of Hepatocellular Carcinoma by Triggering the Wnt/β-Catenin Signaling Pathway.
- Potentiation of Sorafenib's Action by Berberine via Suppression of the mTOR Signaling Pathway in Human Hepatoma Cells.
- Identification of transarterial chemoembolization candidates in advanced hepatocellular carcinoma patients classified solely by performance status 1: a multicenter retrospective study.
- PRR34-AS1 promotes mitochondrial division and glycolytic reprogramming in hepatocellular carcinoma cells through upregulation of MIEF2.
- RARRES1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with SPINK2.
- M6A modification-mediated LIMA1 promotes the progression of hepatocellular carcinoma through the wnt-βcatenin/Hippo pathway.
- Integrating multi-omics techniques and in vitro experiments reveals that GLRX3 regulates the immune microenvironment and promotes hepatocellular carcinoma cell proliferation and invasion through iron metabolism pathways.
- Elucidating the multifaceted role of MGAT1 in hepatocellular carcinoma: integrative single-cell and spatial transcriptomics reveal novel therapeutic insights.
- PPM1G and its diagnostic, prognostic and therapeutic potential in HCC (Review).
- KLF7 Promotes Hepatocellular Carcinoma Progression Through Regulating SLC1A5-Mediated Tryptophan Metabolism.
- The Chemo-Immunotherapeutic Roles of Tumor-Derived Extracellular Vesicle-Based Paclitaxel Delivery System in Hepatocarcinoma.
- Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.
- Elevated STIL predicts poor prognosis in patients with hepatocellular carcinoma.
- Circular RNA circ_0073181 contributes to tumorigenesis by regulating protein tyrosine phosphatase receptor type E via miR-548p in hepatocellular carcinoma.
- Knockdown of long noncoding RNA HUMT inhibits the proliferation and metastasis by regulating miR-455-5p/LRP4 axis in hepatocellular carcinoma.
- Single-cell RNA Sequencing Analysis Reveals New Immune Disorder Complexities in Hypersplenism.
- The role of UXT in tumors and prospects for its application in hepatocellular carcinoma.
- Prefoldin and prefoldin-like complex subunits as predictive biomarkers for hepatocellular carcinoma immunotherapy.
- CircWHSC1 serves as an oncogene to promote hepatocellular carcinoma progression.
Cancer
Osteosarcoma
骨肉瘤Led 5 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Taiyuan for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led5
- The synergistic role of ferroptosis in osteosarcoma immunotherapy.
- Establishment and validation of systematic prognostic nomograms in patients over 60 years of age with osteosarcoma: A multicenter external verification study.
- Research trends and hotspots in the immune microenvironment related to osteosarcoma and tumor cell aging: a bibliometric and visualization study.
- Studies related to osteosarcoma and metabolism from 1990 to 2022: A visual analysis and bibliometric study.
- Endocrine regulation and metabolic mechanisms of osteopontin in the development and progression of osteosarcoma, metastasis and prognosis.
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Taiyuan for multiple myeloma178 hospitals in China for multiple myeloma
No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led2
Chinese-language papers (not in the count)2
Blood disorders
Aplastic anaemia
再生障碍性贫血Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Taiyuan for aplastic anaemia63 hospitals in China for aplastic anaemia
No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led2
Chinese-language papers (not in the count)1
Other diseases
IgG4-related disease
IgG4相关性疾病Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Taiyuan for IgG4-related disease46 hospitals in China for IgG4-related disease
No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Taiyuan for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Taiyuan for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led3
- Cd16-Cd56bright NK Cells: A Protective NK Cell Subset for Progression and Prognosis in Amyotrophic Lateral Sclerosis.
- Association between cardiac autonomic dysfunction, cognitive impairment, and survival in patients with amyotrophic lateral sclerosis.
- Astrocytes Contribute to Motor Neuron Degeneration in ALS via the TRAIL-DR5 Signaling Pathway.
Other diseases
Gaucher disease
戈谢病Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Taiyuan for Gaucher disease41 hospitals in China for Gaucher disease
No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Getting in touch
Name card to show staff or a driver
山西医科大学第三医院
Third Hospital of Shanxi Medical University
太原
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
No hospital-level ROR record matched.